Skip to main content

Pediatric Cancer Experts and Information for Media

St. Jude Children’s Research Hospital has the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude freely shares research and clinical discoveries to ensure doctors and scientists worldwide have the necessary knowledge to help save more children.

Our clinicians and researchers offer credible information, expert insight and thoughtful commentary on today’s news and discoveries on pediatric cancer research and care.

Learn more about the St. Jude Comprehensive Cancer Center and our approach to pediatric oncology.

The following pediatric cancer experts are available to speak to journalists on a range of topics related to research and therapies.

To schedule interviews or speak with one of our experts, email media@stjude.org or contact one of our media relations staff.

Contact Media Relations

Pediatric Cancer Experts

  • James R. Downing, MD

    James Downing, MD, is president and chief executive officer at St. Jude Children's Research Hospital, as well as the hospital’s chair of Childhood Cancer Treatment. He also directs the molecular pathology laboratory, where his research focuses on human leukemia. This laboratory investigates the role of chromosomal translocations in the development of pediatric cancers and determines how the identification of these genetic errors can be used to aid in the diagnosis and management of pediatric patients. Downing was instrumental in launching the Pediatric Cancer Genome Project, and was a finalist of TIME magazine's 100 most influential people in the world.

  • Ching-Hon Pui, MD

    Ching-Hon Pui, MD, is the Oncology chair at St. Jude Children's Research Hospital and is director of the China Region for St. Jude Global. One focus of his research is improving combination chemotherapy to increase cure rates while improving the quality of life during treatment and in survivorship. He advocates for avoiding bone marrow transplantation and subsequent radiation, if possible. Other research interests include evaluating the efficacy of novel anti-leukemic drugs or new therapeutic strategies, and applying molecular genetic, pharmacologic and immunologic discoveries to clinical problems.

  • Charles W. M. Roberts, MD, PhD

    Charles Roberts MD, PhD, is the St. Jude Comprehensive Cancer Center director, which is the only National Cancer Institute (NCI)–designated Comprehensive Cancer Center devoted solely to children. His research in the field of cancer epigenetics has helped lead to new investigational cancer therapies for both children and adults. The Roberts lab studies a molecule (SFN5) that normally suppresses tumors, according to preclinical studies. The molecule is a core member of a chromatin remodeling complex that normally allows access to DNA so genes can be transcribed. Mutated molecules in the complex occur in 20% of all human cancers. Roberts can provide information associated with studies that provide ground-breaking treatments for cancer in adults and children.

  • Carlos Rodriguez-Galindo, MD

    Carlos Rodriguez-Galindo, MD

    Rodriguez-Galindo

    Carlos Rodrigues-Galindo, MD, chairs the St. Jude Global Pediatric Medicine department and serves as the director of St. Jude Global. An alliance he was instrumental in forming in 2018, St. Jude Global aims to improve both the access to and quality of care children receive globally, as well as to provide better treatment options for children worldwide. The current strategic plans of the alliance include the development of regional networks for education and capacity expansion, as well as the research which is fundamental to St. Jude’s mission. Rodriguez-Galindo can be contacted about his research and expertise in global medicine and pediatric solid tumors.

Close